

Description of Additional Supplementary Files

File name: Supplementary Data

Description: Supplementary Data 1-15 presented as a single xlsx-file.

Supplementary Data 1

Description: Characteristics of control and POAG groups

Supplementary Data 2

Description: Comparison of demographic characteristics and comorbidities in patient groups

Supplementary Data 3

Description: Effect of antiglaucomatous therapy on zinc content in AH

Supplementary Data 4

Description: Nomenclature of identified AH metabolites

Supplementary Data 5

Description: AH metabolites characterized by significant ($p < 0.05$ and/or VIP score > 1) changes in stage 2 POAG

Supplementary Data 6

Description: AH metabolites characterized by significant ($p < 0.05$ and/or VIP score > 1) changes in stage 3 POAG

Supplementary Data 7

Description: AH metabolites characterized by significant ($p < 0.05$ and/or VIP score > 1) changes in total POAG

Supplementary Data 8

Description: Summary of AH metabolites characterized by significant changes in POAG

Supplementary Data 9

Description: Effect of antiglaucomatous therapy on metabolites content in AH

Supplementary Data 10

Description: AH proteins assigned to the constitutive AH proteome and presented in the PDB database containing potential Zn^{2+} -binding sites as predicted by the ZincBindPredict program

Supplementary Data 11

Description: AH proteins assigned to the constitutive AH proteome and presented in the PDB and AlphaFold databases containing potential Zn^{2+} -binding sites as predicted by the ZincBindPredict program

Supplementary Data 12

Description: Optimized AAS measurement program

Supplementary Data 13

Description: Summary of the data processing statistics. The values in parentheses refer to the highest-resolution shell. Friedel's pairs are unmerged.

Supplementary Data 14

Description: Crystallographic data and refinement statistics for the final models.

Supplementary Data 15

Description: The source data underlying the plots in the main figures.